Company: NCEL
Filing Date: 2025-10-29
Form Type: 6-K
Source: 0001213900-25-103226
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-10-29
Form: 6-K
Chunk 2
---
 reference.

Upon effectiveness of the Reverse Split and the Merger, the Company will have (i) 4,558,378 common shares, par value CHF 0.05 issued and
outstanding, (ii) 1,060,574 total outstanding common shares, par value CHF 0.05, issuable upon the exercise of pre-funded warrants issued
as Merger consideration, (iii) 13,778 preferred shares, par value CHF 0.05 issued and outstanding, and (iv) 58,320 preferred participation
certificates, par value CHF 0.05 issued and outstanding.

A notice of the Reverse Split
will be filed with the commercial registry of the Canton of Zurich, Switzerland, on October 30, 2025. As a result, the Reverse Split will
become effective in Switzerland on October 30, 2025, and will be reflected on Nasdaq at market open. Following its effectiveness in Switzerland,
the reverse split will be published in the Swiss Official Gazette of Commerce (SOGC) on or around October 31, 2025.

On October 29, 2024, the Registrant
issued a press release titled: “NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with
Proposed Merger with Kadimastem.” A copy of this press release is furnished herewith as Exhibit 99.1.

<div align='center'>1

EXHIBIT INDEX</div>

| Exhibit 
 Number  |     | Description of Document                                                                                                                                   |
| 99.1    |     | Amended and Restated Articles of Association.                                                                                                             |
| 99.2    |     | Press release titled: “NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem.” |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: October 29, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander C. Zwyer |                         |
|:-----------------------|:-----------------------|:-----------------------|:------------------------|
|                        |                        | Name